genesis is mediated by metabolic conversion of the parent hydrocarbon to reactive electrophilic intermediates, the most Dennis Johnston, Thomas J.Slaga and Michael C.MacLeod 2 prominent of which are vicinal diol epoxides (2-4). Indeed, DNA adducts derived from PAH can be detected in DNA In contrast to this, most experimental carcinogenesis protonumber of bolus doses applied intragastrically. In contrast cols use small numbers of relatively large bolus doses of PAH to this, typical human exposures to carcinogens are thought to achieve a high tumor incidence in a relatively short to be at lower doses and to occur with chronic or sporadic observation period. A good example of this can be found in timing. When the classical dosage (1 mg DMBA given once classical mammary tumorigenesis models in mice treated a week for 6 weeks) was split into five daily doses of 200 µg intragastrically with 7,12-dimethylbenz[a]anthracene given intragastrically to female SENCAR mice each week (DMBA), which typically use daily doses of 1 mg/mouse, for 6 weeks, toxicity was high and the major tumor type given six times at weekly intervals (7-10). This corresponds seen was lymphoma. Lowering the dose to 60 µg/day gave to~50 mg/kg body wt and induces mammary tumors in Ͼ50% less toxicity, a 75% incidence of lymphoma and a 30%
are rare. This suggests that the more common mode of human Existing models of mouse mammary carcinogenesis induced exposure is likely to be through multiple, relatively low dose by the model polycyclic aromatic hydrocarbon 7,12-exposures, occurring sporadically or chronically.
dimethylbenz[a]anthracene (DMBA) typically use a small
In contrast to this, most experimental carcinogenesis protonumber of bolus doses applied intragastrically. In contrast cols use small numbers of relatively large bolus doses of PAH to this, typical human exposures to carcinogens are thought to achieve a high tumor incidence in a relatively short to be at lower doses and to occur with chronic or sporadic observation period. A good example of this can be found in timing. When the classical dosage (1 mg DMBA given once classical mammary tumorigenesis models in mice treated a week for 6 weeks) was split into five daily doses of 200 µg intragastrically with 7,12-dimethylbenz[a]anthracene given intragastrically to female SENCAR mice each week (DMBA), which typically use daily doses of 1 mg/mouse, for 6 weeks, toxicity was high and the major tumor type given six times at weekly intervals (7) (8) (9) (10) . This corresponds seen was lymphoma. Lowering the dose to 60 µg/day gave to~50 mg/kg body wt and induces mammary tumors in Ͼ50% less toxicity, a 75% incidence of lymphoma and a 30%
of treated mice in a number of strains. While this protocol is incidence of mammary carcinoma. However, 20 µg DMBA convenient and sufficient for numerous studies, there are cases given five times per week for 6 weeks resulted in a 65-in which an exposure that more closely parallels the expected 70% incidence of mammary carcinoma within~50 weeks.
mode of human exposure would be desirable. In particular, This represents a 50-fold lower daily dosage of DMBA studies of chemoprevention agents that target the initiation than that used in the classical model. DNA was prepared phase of carcinogenesis, namely the events leading up to DNA from 10 mammary adenocarcinomas and 10 lymphomas adduct formation, would be facilitated by lower dose exposures. and exons 1 and 2 of the H-ras1, K-ras and N-ras genes
With this in mind, we have altered the classical model, as were sequenced using PCR techniques. Mutations altering utilized in SENCAR mice by Fischer and colleagues (10), by codons 12 or 61 of one of the ras family genes were found splitting the weekly dose of 1 mg DMBA into smaller doses in 4/10 mammary carcinomas and 5/10 lymphomas. Three given five times per week. We now present a model in which mammary tumors exhibited codon 61 mutations, one in a daily dose of 20 µg DMBA, corresponding to 1/50 of the each of the genes studied, and a fourth tumor contained a classical daily dose, produces mammary carcinomas in 70% codon 12 mutation in the K-ras gene. Among the of mice within a 50 week observation period. Interestingly, at lymphomas, two mutations in codon 12 of K-ras, one higher doses a shift in target specificity towards lymphomamutation in codon 61 of K-ras and two mutations in codon genesis is seen in this model. 61 of N-ras were also found. Each of the mutations could be interpreted as a G→T or A→ T transversion. It is Materials and methods suggested that the high incidence of lymphoma at the higher, repetitive doses may be related to immunotoxicity.
Introduction
(20 mice/group) and AIN-76A semi-purified diet was given ad libitum for the duration of the experiment. After 2 weeks of feeding AIN-76A, groups of Polycyclic aromatic hydrocarbons (PAH*) are a well-studied mice (weight 25-35 g) were treated intragastrically with 0.1 ml corn oil class of environmental contaminants that are implicated as containing 0, 20, 60 or 200 µg/day DMBA, 5 days per week, for 6 weeks human carcinogens (1,2). Based primarily on experimental (total DMBA dose 0, 0.6, 1.8 or 6 mg/mouse respectively). Body weights of studies in rodents and in vitro, it is thought that PAH carcinomice and food intake were recorded weekly until termination. Animals were examined daily for any palpable tumors and for morbidity. When tumors reached~1 cm diameter size, the mice were killed. Moribund mice without *Abbreviations: PAH, polycyclic aromatic hydrocarbons; DMBA, 7,12-dimethylbenz[a]anthracene; MNU, N-methylnitrosourea. palpable tumors were killed and necropsies were carried out immediately. were found prior to termination of the experiment 47 weeks after the last dose of DMBA was administered. In summary, two opposite dose-dependent relationships were seen: (i) the higher the dose, the higher the lymphoma incidence; (ii) the lower the dose, the higher the mammary tumor incidence. The time course of DMBA-induced tumorigenesis, for either lymphoma or mammary tumors, also showed a dose-dependent relationship: the higher the dose, the earlier the time of onset (Figure 2) . However, analysis of the tumor incidence curves was complicated by the relatively high level of toxicity in the high dose group and by the appearance of two distinct tumor types in all groups. Since the time of onset of fatal tumors was dose dependent and the dose dependence appeared to be different for the two tumor types, the final expected surviving fraction if all other deaths were prevented is plotted in Figure 3 for lymphomas ( Figure 3A ) and mammary omas began to appear around week 20 (Figure 2 , closed cancers ( Figure 3B ). This analysis suggests that at the 60 µg circles). Mammary tumor incidence increased to 65% 47 weeks dose rate the relative risk of mammary cancer is greater than after the last treatment and lymphoma incidence was 25% that at the 20 µg dose rate, even though the final incidence (Figure 2) . The higher incidence of mammary tumors over (Figure 2 ) is lower. Statistical comparisons of the survival lymphomas at this low dose is similar to the previous model curves by the Breslow-Gehan-Wilcoxon test indicated a signi-(10), but in contrast to our findings at the higher doses. In the ficant difference between the 20 and 60 µg dose rates for both mammary cancer and lymphoma (P Ͻ 0.05). control group, only one lymphoma and no mammary tumors a The risk of death from lymphoma in mice treated with 60 µg/day DMBA was calculated from the censored incidence data. The estimated mean time to 25, 50 and 75% mortality is tabulated. b Data from Experiment 1 (n ϭ 20 mice) are presented in full in Figure 4 . Experiment 2 was a repetition using a larger number of animals (n ϭ 38).
Results

Total
Several different anatomical locations for lymphoma occurrence were seen. Among mice with a single macroscopic tumor (local lymphoma), the site of occurrence was either a mammary gland-associated lymph node or the thymus. In the 60 µg group, thymic lymphoma, often well advanced, was found in 40% of mice (Table II) . In mice with multiple tumors (systemic lymphoma), Peyer's patches, mesenteric lymph nodes and spleen were also involved. Systemic lymphomas were more common than local lymphoma (10/15 in the 60 µg group, 7/ 10 in the 200 µg group) and were sometimes found to infiltrate other organs, including liver, kidney, ovary and muscle. Lymphoblastic lymphoma and reticulum cell sarcoma were identified among the tumors, but most of the lymphomas could not be further classified from the histopathology slides.
Mammary tumors also appeared of different types. Adenocarcinoma resembling Dunn's type B was the most common tumor seen, but acanthomas, undifferentiated and unclassified carcinomas were also found. Histopathology of tumors characteristic of this model have been presented previously (10). Most mammary tumors were single and localized in the anterior thoracic glands. In addition to mammary tumors and lymphomas, other tumors including ovarian tumors, myomas and endometrial tumors were occasionally found.
To verify the high lymphoma incidence found in the intermediate dose group, a second trial with the 60 µg/day protocol was initiated with a larger number of mice (n ϭ 38). Incidence curves for both lymphomas and mammary carcinomas were similar to those in the first experiment (data not shown). The final incidences of lymphomas and mammary carcinomas were 71 and 26% respectively. Three points (25, 50 and 75% survival) from the Kaplan-Meyer survival curves in the two experiments are compared in Table III, indicating that the survival times were very similar for both tumor types.
Molecular correlates of tumorigenesis
Mutation of the H-ras1 gene is a common feature of DMBA- tumors (16) and transgenic mice that overexpress the Nras gene exhibit a high spontaneous incidence of mammary carcinomas (17) . K-ras mutations have been described in groups and amplified known mutational hotspots in the Hras1, K-ras and N-ras genes by PCR using primers specific MNU-induced T cell lymphomas in mice (18, 19) .
To begin to determine whether mutations of ras family for exons 1 and 2 of these genes. The amplification products were then sequenced by cycle sequencing with Taq polymerase; genes are involved in mammary tumorigenesis in the low dose model, we isolated genomic DNA from 10 representative examples of the wild-type and mutant sequences obtained from each of these genes are shown in Figure 4 . Using these adenocarcinomas from mice in the 20 and 60 µg/day DMBA such a high incidence of lymphoma (up to 50-70%) was seen to their dose schedule, suggesting that immunosuppression may also occur in the DMBA-treated SENCAR mice. It is possible that immunosuppression, particularly cytotechniques we identified 4/10 mammary tumors with apparent toxicity in the lymphocyte populations, becomes a key factor mutations (Table IV) , two in the K-ras, one in the N-ras and in the development of lymphoid neoplasia when the lymphoid one in the H-ras1 gene. All detected mutations were in codons system is repeatedly exposed to a high enough dose of 12 and 61, previously noted hotspots for DMBA-induced carcinogen. A pharmacokinetics study in B6C3F1 mice indimutations in several tumorigenesis models, and all mutations cated that DMBA was nearly completely eliminated within were A→T or G→T transversions, consistent with previously 24 h when a single dose was administered. The highest tissue noted DMBA mutational spectra.
concentrations of DMBA were detected in gut-associated Mutations in ras family genes were also detected in genomic lymphoid tissues and the peak level was reached in this DNA purified from 10 representative lymphomas produced in lymphoid tissue 2 h earlier than that in serum, suggesting the repetitive, low dose DMBA model (Table IV) . Half of the DMBA first appeared in and had a high affinity for lymphoid lymphomas tested exhibited a mutation in either codon 12 or tissue. The amount of covalent binding of [ 3 H]DMBA in 61 of either the N-ras or K-ras genes, similar to the findings spleen was 2-fold higher than that in the other organs (27) . In among the mammary tumors. Again, all the mutations were our high frequency approach, at the two higher dose rates the apparently A→T or G→T transversions and all altered the immunological system was repeatedly exposed to necrogenic predicted amino acid sequence of the protein.
doses of DMBA. The resulting, almost continuous cytotoxicity and mutagenic activity would have assured that proliferating Discussion cells were exposed to the mutagenic activity of DMBA and may have resulted in a very high potential to produce The three doses of DMBA used in these studies produced three very different effects. The highest dose of DMBA lymphoma. Based on the data from B6C3F1 mice (25) , the lowest dose used here (20 µg/day) may not have been necro-(200 µg) caused acute toxicity, affecting~40% of the mice within 10 weeks, and produced lymphomas in most of the genic for lymphoid tissue and therefore did not lead to high levels of lymphomagenesis. With a longer interval between remaining mice. Reducing the daily DMBA dose to 60 µg prevented the toxicity and induced lymphomas in 75% of the doses, even the much higher dose (1 mg once a week) may not be lymphomagenic. Because the lymphoid system is a mice. The remaining mice developed mammary tumors. The lowest dose of DMBA resulted in a high incidence of mammary very proliferative tissue, it may recover a normal population within 1 week, before the next toxic and mutagenic exposure tumors and a correspondingly lower incidence of lymphomas. From these results, it appears that the intermediate dose (60 to DMBA. So we may hypothesize that strong and continuing DMBA-induced immunosuppression (hormone and other facµg) may represent an advantageous new lymphomagenesis model, because only a short observation time (~25 weeks) is tors may be involved, see below) may be a key factor in causing lymphoid neoplasia. needed. The low dose DMBA (20 µg) model may be advantageous to study mammary tumorigenesis, with 1/10 of the total The molecular mechanism of immunosuppression by DMBA is still not clear. An important question is whether the parent dose used in the previous model (10) and only 1/50 of the daily dose. The drawbacks are the increased manipulation of compound, DMBA, or metabolites of DMBA are responsible for the immunosuppressive effect. Some studies have shown the animals during dosing and the longer observation time.
DMBA-induced lymphoma was reported after percutaneous that unmetabolized DMBA has immunosuppressive effects and metabolism is not necessary (24, 28) . However, other studies treatment (100 µg twice weekly for 7 weeks) in DBA/2 mice; tumor incidence can reach 100% with a short latency period.
indicated that metabolism by cytochrome P450 IA1 is required for DMBA to produce immunosuppression. When purified This strain is homozygous for the recessive Ah d allele and is not inducible for aryl hydrocarbon hydroxylase activity (20).
metabolites were studied, one metabolite had 65-fold more potent immunosuppressive effects than the parent compound If mice are homozygous or heterozygous for the dominant Ah b allele, like C57BL/6 mice, aryl hydrocarbon hydroxylase is DMBA (29) . Thus, it seems likely that both DMBA and some metabolites of DMBA can produce immunosuppressive effects. inducible and they are susceptible to skin tumors after treatment with DMBA (20). SENCAR mice are also sensitive for DMBAHowever, metabolites of DMBA that can cause immunosuppressive effects may not be produced in large enough induced skin cancer after topical application (21). However, in SENCAR mice, Fischer and colleagues reported only amounts in vivo and therefore DMBA itself may play a dominant role in immunosuppression. In other words, DMBA 13% lymphoma incidence after weekly oral administration of DMBA (total dose 6 mg; 10). The obvious question is why itself may indirectly enhance tumorigenesis through damage
